845 related articles for article (PubMed ID: 28196509)
1. Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants.
Ebner M; Birschmann I; Peter A; Spencer C; Härtig F; Kuhn J; Blumenstock G; Zuern CS; Ziemann U; Poli S
Crit Care; 2017 Feb; 21(1):32. PubMed ID: 28196509
[TBL] [Abstract][Full Text] [Related]
2. Emergency Coagulation Assessment During Treatment With Direct Oral Anticoagulants: Limitations and Solutions.
Ebner M; Birschmann I; Peter A; Härtig F; Spencer C; Kuhn J; Blumenstock G; Zuern CS; Ziemann U; Poli S
Stroke; 2017 Sep; 48(9):2457-2463. PubMed ID: 28775134
[TBL] [Abstract][Full Text] [Related]
3. Point-of-Care Testing of Coagulation in Patients Treated With Non-Vitamin K Antagonist Oral Anticoagulants.
Ebner M; Peter A; Spencer C; Härtig F; Birschmann I; Kuhn J; Wolf M; Winter N; Russo F; Zuern CS; Blumenstock G; Ziemann U; Poli S
Stroke; 2015 Oct; 46(10):2741-7. PubMed ID: 26272385
[TBL] [Abstract][Full Text] [Related]
4. Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study.
Testa S; Legnani C; Tripodi A; Paoletti O; Pengo V; Abbate R; Bassi L; Carraro P; Cini M; Paniccia R; Poli D; Palareti G
J Thromb Haemost; 2016 Nov; 14(11):2194-2201. PubMed ID: 27566988
[TBL] [Abstract][Full Text] [Related]
5. Measurement of dabigatran, rivaroxaban and apixaban in samples of plasma, serum and urine, under real life conditions. An international study.
Harenberg J; Du S; Wehling M; Zolfaghari S; Weiss C; Krämer R; Walenga J
Clin Chem Lab Med; 2016 Feb; 54(2):275-83. PubMed ID: 26167981
[TBL] [Abstract][Full Text] [Related]
6. Point-of-care coagulation testing for assessment of the pharmacodynamic anticoagulant effect of direct oral anticoagulant.
Mani H; Herth N; Kasper A; Wendt T; Schuettfort G; Weil Y; Pfeilschifter W; Linnemann B; Herrmann E; Lindhoff-Last E
Ther Drug Monit; 2014 Oct; 36(5):624-31. PubMed ID: 24577124
[TBL] [Abstract][Full Text] [Related]
7. Limitations of Specific Coagulation Tests for Direct Oral Anticoagulants: A Critical Analysis.
Ebner M; Birschmann I; Peter A; Härtig F; Spencer C; Kuhn J; Rupp A; Blumenstock G; Zuern CS; Ziemann U; Poli S
J Am Heart Assoc; 2018 Oct; 7(19):e009807. PubMed ID: 30371316
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays.
Gosselin R; Grant RP; Adcock DM
Int J Lab Hematol; 2016 Oct; 38(5):505-13. PubMed ID: 27265752
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the DOAC-Stop Procedure by LC-MS/MS Assays for Determining the Residual Activity of Dabigatran, Rivaroxaban, and Apixaban.
Slavik L; Jacova J; Friedecky D; Ulehlova J; Tauber Z; Prochazkova J; Hlusi A; Palova M
Clin Appl Thromb Hemost; 2019; 25():1076029619872556. PubMed ID: 31523979
[TBL] [Abstract][Full Text] [Related]
10. Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants including edoxaban.
Härtig F; Birschmann I; Peter A; Hörber S; Ebner M; Sonnleitner M; Spencer C; Bombach P; Stefanou MI; Tünnerhoff J; Mengel A; Kuhn J; Ziemann U; Poli S
Neurol Res Pract; 2021 Mar; 3(1):9. PubMed ID: 33641678
[TBL] [Abstract][Full Text] [Related]
11. Point of Care Testing (POCT) to assess drug concentration in patients treated with non-vitamin K antagonist oral anticoagulants (NOACs).
Padayattil Jose S; Banzato A; Carraro P; Haleh A; Rossi K; Nante G; Denas G; Zoppellaro G; Pengo V
Thromb Res; 2018 Mar; 163():100-104. PubMed ID: 29407620
[TBL] [Abstract][Full Text] [Related]
12. Multianalyte Determination of NOACs Using LC-MS/MS and Comparison with Functional Coagulation Assays.
Slavik L; Lukes J; Friedecky D; Zhanelova M; Nemcova M; Ulehlova J; Prochazkova J; Hlusi A; Palova M; Vaclavik J
Clin Lab; 2018 Oct; 64(10):1611-1621. PubMed ID: 30336535
[TBL] [Abstract][Full Text] [Related]
13. Interlaboratory variability in the measurement of direct oral anticoagulants: results from the external quality assessment scheme.
Tripodi A; Chantarangkul V; Legnani C; Testa S; Tosetto A
J Thromb Haemost; 2018 Mar; 16(3):565-570. PubMed ID: 29322630
[TBL] [Abstract][Full Text] [Related]
14. Influence of DOAC Stop on coagulation assays in samples from patients on rivaroxaban or apixaban.
Platton S; Hunt C
Int J Lab Hematol; 2019 Apr; 41(2):227-233. PubMed ID: 30468572
[TBL] [Abstract][Full Text] [Related]
15. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants.
Cuker A; Siegal DM; Crowther MA; Garcia DA
J Am Coll Cardiol; 2014 Sep; 64(11):1128-39. PubMed ID: 25212648
[TBL] [Abstract][Full Text] [Related]
16. The effect of DOAC-Stop on lupus anticoagulant testing in plasma samples of venous thromboembolism patients receiving direct oral anticoagulants.
Ząbczyk M; Kopytek M; Natorska J; Undas A
Clin Chem Lab Med; 2019 Aug; 57(9):1374-1381. PubMed ID: 30763261
[TBL] [Abstract][Full Text] [Related]
17. A Practical Guide to Ordering and Interpreting Coagulation Tests for Patients on Direct Oral Anticoagulants in Singapore.
Wong WH; Yip CY; Sum CL; Tan CW; Lee LH; Yap ES; Kuperan P; Ting WC; Ng HJ
Ann Acad Med Singap; 2016 Mar; 45(3):98-105. PubMed ID: 27146462
[TBL] [Abstract][Full Text] [Related]
18. The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples.
Bonar R; Favaloro EJ; Mohammed S; Ahuja M; Pasalic L; Sioufi J; Marsden K
Pathology; 2016 Jan; 48(1):60-71. PubMed ID: 27020211
[TBL] [Abstract][Full Text] [Related]
19. Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography - tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants.
Schmitz EM; Boonen K; van den Heuvel DJ; van Dongen JL; Schellings MW; Emmen JM; van der Graaf F; Brunsveld L; van de Kerkhof D
J Thromb Haemost; 2014 Oct; 12(10):1636-46. PubMed ID: 25142183
[TBL] [Abstract][Full Text] [Related]
20. Laboratory determination of old and new targeted anticoagulant agents for prevention of bleeding and thrombotic events in cancer patients.
Harenberg J
Thromb Res; 2016 Apr; 140 Suppl 1():S165-7. PubMed ID: 27067972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
